SSRI and SNRI Choice in PTSD: Does FDA Approval Reflect Real Superiority?
Only sertraline and paroxetine carry an FDA indication for PTSD. Whether that regulatory fact tracks real pharmacologic superiority, or simply which manufacturers ran the required trials, is a genuinely separate question.
J.M. is a 42-year-old man who has taught high school auto shop for eleven years and remarried last spring; he tells the intake coordinator this is the first time in eighteen years he has sat across from a psychiatrist, not because anything is new but because his wife noticed how little he actually sleeps. His symptoms trace back to two deployments in his twenties — recurring nightmares, a startle response he has learned to hide at work, and a habit of checking exits in restaurants he has never mentioned to anyone before this visit. He has mild hypertension, managed for about four years on lisinopril, and is otherwise in good health; he has never taken a psychiatric medication.
The reflex answer is sertraline, one of only two agents — alongside paroxetine — carrying an FDA indication specifically for PTSD. But that approval history is narrower than it looks: both indications were established in trials run in the late 1990s by the specific manufacturers who chose to pursue the PTSD label at the time it became a recognized regulatory category, not by a head-to-head comparison against other antidepressants. Venlafaxine extended-release has its own positive, adequately powered placebo-controlled trial in PTSD; fluoxetine has multiple positive trials predating the two approved agents by several years. Neither drug's sponsor brought a PTSD-specific application to the FDA afterward — a commercial and regulatory-strategy choice, not a signal that the trials failed. J.M.'s own profile complicates the reflex answer further: paroxetine's anticholinergic load and weight-gain liability sit awkwardly against a fit, physically active tradesman who is already worried about medication side effects undermining a marriage he describes as the best thing that has happened to him in a decade.
At the intake visit
Start with sertraline. It is the best-studied agent in this specific population, it carries the regulatory backing of a dedicated indication, and defaulting to the approved option is the right instinct precisely because it removes one layer of uncertainty from a first-ever psychiatric medication trial.
If his hypertension were poorly controlled or he were on an interacting antihypertensive, I'd weigh this differently — sertraline's interaction profile with lisinopril is not a concern here, which is part of why it stays the simplest starting point.
The FDA indication is doing more work in this conversation than it should. Two companies ran the specific trials the agency wanted at a particular moment in the late 1990s; that is a fact about who filed paperwork, not a fact about comparative efficacy. Venlafaxine ER has its own solid placebo-controlled trial in PTSD, and fluoxetine has an even longer track record in the same population.
For a man this specifically worried about weight gain and about anything that could interfere with the marriage he just described, paroxetine's side-effect burden is the wrong tradeoff even though it shares sertraline's regulatory status.
Both of you are converging on sertraline anyway, just by different roads — one from the label, one from ruling out the alternative that shares the label. That agreement is worth naming explicitly to him: he is getting the approved agent because its tolerability profile actually fits him, not because the FDA said so. Venlafaxine stays the documented fallback if he doesn't respond, since the evidence there is real even without the indication attached to it.
Sertraline started at 25 mg, with a plan to titrate toward 100 mg over several weeks as tolerated, and a follow-up visit in four weeks.
The team's explicit agreement, worth recording because it reframes the reasoning rather than just the outcome: sertraline was chosen because its actual tolerability profile fit this patient, not because its FDA indication settled the question on its own. Venlafaxine ER remains the documented, evidence-backed next step if sertraline is not tolerated or does not work — not a lesser option chosen only after the "real" first-line agents fail.